Compare KWR & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KWR | HROW |
|---|---|---|
| Founded | 1918 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1994 | N/A |
| Metric | KWR | HROW |
|---|---|---|
| Price | $128.27 | $37.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $159.75 | $69.86 |
| AVG Volume (30 Days) | 153.1K | ★ 475.4K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,888,634,000.00 | N/A |
| Revenue This Year | $5.31 | $31.79 |
| Revenue Next Year | $4.02 | $49.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.66 | N/A |
| 52 Week Low | $98.26 | $21.18 |
| 52 Week High | $183.01 | $54.98 |
| Indicator | KWR | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 52.71 |
| Support Level | $125.96 | $36.23 |
| Resistance Level | $127.86 | $41.49 |
| Average True Range (ATR) | 4.69 | 1.53 |
| MACD | 1.87 | 0.76 |
| Stochastic Oscillator | 77.04 | 86.46 |
Quaker Houghton manufactures and sells a variety of industrial process fluids. The company's product portfolio includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company's geographic segments include the Americas, EMEA, and Asia/Pacific. The majority of the company's revenue is earned from the Americas.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.